PTPRQ
Overview
PTPRQ (Protein Tyrosine Phosphatase Receptor Type Q) is a receptor-type protein tyrosine phosphatase involved in cellular signaling. In cancer genomics, PTPRQ has been identified as a focal amplification target in dedifferentiated liposarcoma (DDLPS), grouped among adipocyte-differentiation-inhibitor amplifications implicated in the poor-prognosis DDLPS subtype.
Alterations observed in the corpus
- PTPRQ amplified in 46% of DDLPS tumors in the TCGA sarcoma cohort (n=206); grouped among adipocyte-differentiation-inhibitor amplifications alongside JUN (42%), DDIT3 (32%), YAP1 (16%), and CEBPA (24%); JUN amplification defines the poor-prognosis K1 cluster PMID:29100075.
Cancer types (linked)
- DDLPS (dedifferentiated liposarcoma): Focal amplification in 46% of cases; among the most frequently amplified genes after MDM2 (100%), FRS2 (96%), CDK4 (92%), and HMGA2 (76%) in this subtype PMID:29100075.
Co-occurrence and mutual exclusivity
- Co-amplified with JUN, DDIT3, YAP1, and CEBPA in DDLPS as a group of adipocyte-differentiation-inhibitor amplifications PMID:29100075.
Therapeutic relevance
- The amplification of PTPRQ in DDLPS alongside the JUN/Hippo-pathway group nominates the adipocyte-differentiation axis as a therapeutic target in this histotype.
Open questions
- Whether PTPRQ amplification independently drives oncogenesis or is co-amplified passively due to chromosomal proximity in DDLPS is unresolved.
Sources
This page was processed by crosslinker on 2026-05-15.